Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET
Article first published online: 22 DEC 2005
Copyright © 2005 John Wiley & Sons, Ltd.
Journal of Labelled Compounds and Radiopharmaceuticals
Volume 49, Issue 1, pages 17–31, January 2006
How to Cite
Chin, F. T., Morse, C. L., Shetty, H. U. and Pike, V. W. (2006), Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET. J Label Compd Radiopharm, 49: 17–31. doi: 10.1002/jlcr.1016
- Issue published online: 22 DEC 2005
- Article first published online: 22 DEC 2005
- Manuscript Accepted: 21 SEP 2005
- Manuscript Received: 5 AUG 2005
- National Institute of Mental Health
- neurokinin type-1;
[18F]SPA-RQ is an effective radioligand for imaging brain neurokinin type-1 (NK1) receptors in clinical research and drug discovery with positron emission tomography. For the automated regular production of [18F]SPA-RQ for clinical use in the USA under an IND we chose to use a modified commercial synthesis module (TRACERlab FXF-N; GE Medical Systems) with an auxiliary custom-made robotic cooling–heating reactor, after evaluating several alternative radiosynthesis conditions. The automated radiosynthesis and its quality control are described here. [18F]SPA-RQ was regularly obtained within 150 min from the start of radiosynthesis in high radiochemical purity (>99%) and chemical purity and with an overall decay-corrected radiochemical yield of 15±2% (mean±S.D.; n=10) from cyclotron-produced [18F]fluoride ion. The specific radioactivity of [18F]SPA-RQ at the end of synthesis ranged from 644 to 2140 mCi/µmol (23.8–79.2 GBq/µmol). Copyright © 2005 John Wiley & Sons, Ltd.